MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

Search

Merus NV

Open

SectorGezondheidszorg

43.55 0.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

42.43

Max

44.3

Belangrijke statistieken

By Trading Economics

Inkomsten

-31M

Verkoop

9.1M

EPS

-0.49

Winstmarge

-338.326

Werknemers

260

EBITDA

-88M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+101.58% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

354M

3B

Vorige openingsprijs

42.69

Vorige sluitingsprijs

43.55

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Merus NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr 2025, 23:51 UTC

Marktinformatie

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr 2025, 23:37 UTC

Top Nieuws

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr 2025, 23:36 UTC

Top Nieuws

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr 2025, 23:13 UTC

Top Nieuws
Winsten

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr 2025, 23:09 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr 2025, 22:51 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr 2025, 22:48 UTC

Top Nieuws

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr 2025, 22:47 UTC

Marktinformatie

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr 2025, 22:38 UTC

Marktinformatie
Winsten

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr 2025, 22:24 UTC

Marktinformatie
Winsten

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr 2025, 22:23 UTC

Winsten

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr 2025, 22:11 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

24 apr 2025, 22:11 UTC

Marktinformatie
Winsten

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr 2025, 22:09 UTC

Top Nieuws
Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr 2025, 22:00 UTC

Marktinformatie
Winsten

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr 2025, 21:39 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr 2025, 21:23 UTC

Top Nieuws
Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr 2025, 21:04 UTC

Winsten

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr 2025, 21:02 UTC

Winsten

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Vergelijking

Prijswijziging

Merus NV Prognose

Koersdoel

By TipRanks

101.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 89.42 USD  101.58%

Hoogste 110 USD

Laagste 67 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merus NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technische score

By Trading Central

43.215 / 45.9Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.